SRC and colorectal carcinoma: Further investigation will be required to fully explore the molecular mechanisms which confer context‐dependent SRC and MEK inhibitor combination response including testing whether CRC cells with RAS‐G13D mutations and lacking NF1 represent a subtype sensitive to SRC‐MEK inhibitor combinations.